The Vigilant Biosciences® BeVigilant™ RAPID Test is based on patented technology that assesses CD44, a tumor–initiating and stem cell–associated biomarker, and total protein levels–markers clinically validated to be associated specifically with oral cancer when tested in an oral rinse–to aid clinicians in the early detection of oral cancer. The simple, oral rinse procedure is easy to administer and non–invasive for the patient.